Identification of a Novel Estrogen Receptor-α Variant and Its Upstream Splicing Regulator
- 1 May 2010
- journal article
- other
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 24 (5) , 914-922
Abstract
Alternative splicing of precursor mRNA is a fundamental mechanism to generate multiple proteins from a single gene. Although constitutive and alternative mRNA splicing is temporally and spatially regulated, deregulation of mRNA splicing could cause development, progression, and metastasis of tumors. Through yeast two-hybrid screening of a human breast cDNA library using estrogen receptor-α (ERα) as bait, we identified a novel nuclear receptor box containing full-length protein, nuclear protein E3-3 (NPE3-3). Our results revealed that NPE3-3 associates with not only ERα but also with splicing factors, serine/arginine-rich protein (SRp)-30c, SRp40, and splicing factor SC-35, suggesting that NPE3-3 is likely to be involved in regulation of mRNA splicing. Accordingly, transient expression of NPE3-3 in cells resulted in expected splicing of the CD44 control minigene. We also discovered that NPE3-3-overexpressing clones produced a novel, previously unrecognized, alternatively spliced variant of ERα (termed ERαV), which had a molecular size of 37 kDa composed of only exons 1, 2, 7, and 8. ERαV was expressed and sequestered in the cytoplasm in MCF-7 cells stably overexpressing NPE3-3, suggesting its involvement in nongenomic hormone signaling. NPE3-3 clones exhibited up-regulation of ERK1/2 signaling, cyclin D1, and cathepsin D and enhanced tumor cell proliferation, migration, and tumorigenicity. Moreover, direct expression of the ERαV in breast cancer cells stimulated ERK1/2 up-regulation and cyclin D1 expression. We found that ERαV physically interacted with MAPK kinase (MEK)-1/2, and thus, an ERαV and MEK1/2 complex could lead to the activation of the ERK1/2 pathway. Interestingly, NPE3-3 was up-regulated in human breast tumors. These findings revealed a role for NPE3-3 in alternative splicing and suggest that ERα is a physiological target of NPE3-3, leading to a constitutive nongenomic signaling pathway in breast cancer cells.Keywords
This publication has 26 references indexed in Scilit:
- Regulation of Estrogen Rapid Signaling through Arginine Methylation by PRMT1Molecular Cell, 2008
- A variant of estrogen receptor-α, hER-α36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signalingProceedings of the National Academy of Sciences, 2006
- BARX2 and estrogen receptor-α (ESR1) coordinately regulate the production of alternatively spliced ESR1 isoforms and control breast cancer cell growth and invasionOncogene, 2006
- Activation of vascular endothelial growth factor (VEGF) by the ER-α variant, ERΔ3Breast Cancer Research and Treatment, 2005
- Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66Biochemical and Biophysical Research Communications, 2005
- Potentiation of estrogen receptor transcriptional activity by breast cancer amplified sequence 2Biochemical and Biophysical Research Communications, 2005
- Refocusing on BRCA1Nature Cell Biology, 2004
- CD44 Interaction with c-Src Kinase Promotes Cortactin-mediated Cytoskeleton Function and Hyaluronic Acid-dependent Ovarian Tumor Cell MigrationJournal of Biological Chemistry, 2001
- Regulatable Expression of p21-activated Kinase-1 Promotes Anchorage-independent Growth and Abnormal Organization of Mitotic Spindles in Human Epithelial Breast Cancer CellsJournal of Biological Chemistry, 2000
- Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesisOncogene, 1999